Mona Ashiya Sells 83,182 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya sold 83,182 shares of Disc Medicine stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $54.45, for a total value of $4,529,259.90. Following the completion of the transaction, the director now owns 194,209 shares of the company’s stock, valued at approximately $10,574,680.05. This trade represents a 29.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Mona Ashiya also recently made the following trade(s):

• On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The shares were sold at an average price of $54.29, for a total value of $10,974,506.34.

Disc Medicine Stock Up 0.1 %

Disc Medicine stock opened at $53.93 on Thursday. The business has a 50-day simple moving average of $56.62 and a 200 day simple moving average of $55.94. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $68.86. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -13.55 and a beta of 0.73.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.08. On average, research analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Institutional Investors Weigh In On Disc Medicine

Hedge funds have recently added to or reduced their stakes in the company. Sterling Capital Management LLC lifted its stake in Disc Medicine by 798.4% during the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock worth $36,000 after purchasing an additional 503 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in Disc Medicine during the fourth quarter worth about $40,000. Tower Research Capital LLC TRC lifted its stake in Disc Medicine by 47.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after purchasing an additional 266 shares during the last quarter. Quest Partners LLC bought a new stake in Disc Medicine during the third quarter worth about $131,000. Finally, Quantbot Technologies LP bought a new stake in Disc Medicine during the third quarter worth about $146,000. Institutional investors own 83.70% of the company’s stock.

Wall Street Analyst Weigh In

IRON has been the subject of several recent research reports. Scotiabank lifted their price target on Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, March 3rd. Morgan Stanley reiterated an “overweight” rating and issued a $85.00 price target on shares of Disc Medicine in a research report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $118.00 price target on shares of Disc Medicine in a research report on Tuesday, January 21st. Stifel Nicolaus boosted their target price on Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a research report on Friday, January 24th. Finally, TD Cowen began coverage on Disc Medicine in a research report on Thursday, February 27th. They set a “buy” rating for the company. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $89.10.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.